Holdings
T. Rowe Price Health Sciences Portfolio
As of Jun 30, 2026, T. Rowe Price Health Sciences Portfolio reported 161 positions worth US$713M. Largest: Eli Lilly And Company, Johnson & Johnson and Unitedhealth Group Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 88,118 | US$106M | +14,527 | Jun 30, 2026 |
| Johnson & Johnson | 196K | US$49.9M | +130K | Jun 30, 2026 |
| Unitedhealth Group Incorporated | 106K | US$44.2M | +30,452 | Jun 30, 2026 |
| Abbvie Inc. | 153K | US$38.5M | +65,280 | Jun 30, 2026 |
| Merck & Company, Inc. | 234K | US$30M | +43,311 | Jun 30, 2026 |
| Gilead Sciences, Inc. | 166K | US$21M | +42,186 | Jun 30, 2026 |
| Thermo Fisher Scientific Inc | 37,982 | US$19M | −16,959 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 34,183 | US$17M | −1,862 | Jun 30, 2026 |
| Bristol-myers Squibb Company | 276K | US$15.9M | new | Jun 30, 2026 |
| Abbott Laboratories | 159K | US$14.4M | new | Jun 30, 2026 |